Excipient Market Overview: Evonik launches high-purity excipients; India mandates disclosures from March 2026

Data Compilation
#PharmaFlow

Pipeline Prospector November 2025: Kimberly-Clark to buy Kenvue for US$ 48.7 bn; FDA approves Novartis’ gene therapy

Stock Recap
#PipelineProspector

PW-2132

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

50 API Suppliers, 20 USDMF, 19 CEP/COS, 1 JDMF, 7 EU WC, 3 KDMF, 12 NDC API, 34 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

16 Drugs in Development

16 Drugs in Development

INTERMEDIATES

15 Intermediate Suppliers

15 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

256 FDF Dossiers, 48 FDA Orange Book, 155 Europe, 5 Canada, 14 South Africa, 34 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

4 SPI Pharma, 1 DKSH, 8 Boai NKY Pharmaceuticals Ltd, 4 Gangwal Healthcare, 2 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 1 Kirsch Pharma, 1 Alcedo Pharmachem, 6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 2 Ashland, 14 BASF, 1 BioSpectra, 1 Clariant, 6 DFE Pharma, 6 Gangwal Chemicals, 1 Ideal Cures, 3 Ingredion Pharma Solutions, 15 Kerry, 2 Keval Exports, 12 Microlex e.U, 2 Nitika Pharmaceutical Specialities, 2 Novo Excipients, 4 Pharmatrans-Sanaq, 4 Pluviaendo, 3 Prachin Chemical, 15 Roquette, 1 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 9 Sigachi Industries, 3 Silverline Chemicals, 2 Ulanqab Kema New Material, 3 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

50 Fillers, Diluents & Binders, 31 Direct Compression, 29 Disintegrants & Superdisintegrants, 25 Granulation, 15 Thickeners and Stabilizers, 12 Co-Processed Excipients, 12 Lubricants & Glidants, 10 Chewable & Orodispersible Aids, 9 Solubilizers, 6 Parenteral, 6 Controlled & Modified Release, 5 Taste Masking, 4 Coating Systems & Additives, 3 Film Formers & Plasticizers, 3 Topical, 3 Emulsifying Agents, 2 API Stability Enhancers, 2 Rheology Modifiers, 1 Surfactant & Foaming Agents

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 6 News #PharmaBuzz

GLOBAL SALES INFORMATION

11 US Medicaid Prescriptions, 27 Regulatory FDF Prices

MARKET PLACE

12 APIs, 12 FDF Dossiers, 1 Intermediates

PATENTS & EXCLUSIVITIES

2 US Patents

2 US Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 11 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Registrant Name	Registration No.	Compound	Registration Date	Manufacturer	Manufacturer's Country	Manufacturer's Address
29/11/2025	Arevipharma	Germany	Menarini Korea Co., Ltd.	20210630-209-J-1046	torsemide	2021-06-30	Arevipharma GmbH	Germany	Meissner Strasse 35, 01445 Radebeul, Germany
29/11/2025	Ipca Laboratories	India	Sungjin Exim Co., Ltd.	20200212-209-J-562	torsemide	2020-02-12	IPCA Laboratories Limited	India	PO Sejavta, District-Ratlam (MP) 457001, India

PW-2132

PW-2132

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

50 API Suppliers

20 USDMF

19 CEP/COS

1 JDMF

7 EU WC

3 KDMF

12 NDC API

34 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

16 Drugs in Development

INTERMEDIATES

15 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

256 FDF Dossiers

48 FDA Orange Book

155 Europe

5 Canada

14 South Africa

34 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

4 SPI Pharma

1 DKSH

8 Boai NKY Pharmaceuticals Ltd

4 Gangwal Healthcare

2 Nanjing Well Pharmaceutical

1 Pfanstiehl

1 Kirsch Pharma

1 Alcedo Pharmachem

6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

2 Ashland

14 BASF

1 BioSpectra

1 Clariant

6 DFE Pharma

6 Gangwal Chemicals

1 Ideal Cures

3 Ingredion Pharma Solutions

15 Kerry

2 Keval Exports

12 Microlex e.U

2 Nitika Pharmaceutical Specialities

2 Novo Excipients

4 Pharmatrans-Sanaq

4 Pluviaendo

3 Prachin Chemical

15 Roquette

1 Seppic

4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shanghai Welltone Material Technology Co., Ltd

9 Sigachi Industries

3 Silverline Chemicals

2 Ulanqab Kema New Material

3 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

50 Fillers, Diluents & Binders

31 Direct Compression

29 Disintegrants & Superdisintegrants

25 Granulation

15 Thickeners and Stabilizers

12 Co-Processed Excipients

12 Lubricants & Glidants

10 Chewable & Orodispersible Aids

9 Solubilizers

6 Parenteral

6 Controlled & Modified Release

5 Taste Masking

4 Coating Systems & Additives

TABLET;ORAL - 100MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 10MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 20MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 5MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons